


Stockholm, 26 October 2026

BrainZell enters collaboration with Stardots to connect neural organoid research with human measurements



BrainZell and Stardots have established Cross-AI, a research collaboration exploring how drug responses in patient-derived neural organoids relate to measurements in people. By combining the partners' complementary technologies and AI expertise, the collaboration aims to help pharmaceutical teams identify promising drug candidates, stratify trial participants and measure treatment response. Bipolar disorder is the initial research direction.


BrainZell will integrate Stardots' existing Psilmi research platform as a human reference within its own organoid research workflow. Psilmi combines synchronized measurements of pupil dynamics, eye movements and cognitive performance. The collaboration brings together BrainZell's organoid, electrophysiology, experimental and AI expertise with Stardots' human-measurement, platform and AI expertise.

The name Cross-AI reflects **cross-scale artificial intelligence**—connecting human-level measurements from Psilmi with cellular-level activity in BrainZell's neural organoid models.

The research starts with BrainZell's high-throughput organoid arrays, which are used to explore biological targets and test compounds. AI teams from both companies will work together to link laboratory response patterns with Psilmi measurements, including signals that unfold on different time scales. The aim is to investigate how these complementary measurements can inform the understanding of drug responses across cellular models and people.

A selected subset of participants could provide matched human and organoid data. Psilmi's underlying dataset originates from a research project at Uppsala University and is accessed by Stardots through its collaboration with the university. Any use in the programme, including of matched data, remains subject to consent, ethics, data-protection and donor-governance review.


While the collaboration builds on existing technologies, the combined human–organoid approach is at an early research stage. Any predictive or clinical applications would require further validation and, where applicable, regulatory review.



Petra Szeszula
CEO, BrainZell

"This collaboration brings us closer to one of the greatest goals of drug development: predicting patient outcomes from preclinical models. By linking BrainZell's human brain organoids and AI with Psilmi's objective, real-world patient data, we can identify which biological responses truly translate into therapeutic benefit. Together, we can open a new horizon for faster, more precise, and more successful CNS drug development. We look forward to working with the Stardots team to investigate these links and what they could mean for pharmaceutical research,"

says Petra Szeszula, CEO, BrainZell.



Daniel Petrini
CEO, Stardots

"Psilmi brings pupil responses, eye movements and cognitive performance together in one research platform. We are pleased to work with BrainZell to connect those human measurements with complementary cellular models. It is an opportunity for our teams to explore drug response from different scientific perspectives, with a shared interest in questions that matter to pharmaceutical research,"

says Daniel Petrini, CEO, Stardots.

ABOUT BRAINZELL

BrainZell makes human brain drug discovery more predictive with computational models built on a proprietary human brain organoid platform. In Alzheimer's disease research, BrainZell's patient-derived brain organoids have displayed clinically relevant disease phenotypes, and the company has used them to identify molecules that rescue those phenotypes.

ABOUT STARDOTS

Stardots develops Psilmi, a research platform combining synchronized pupil, eye-movement and cognitive measures to study human function and treatment-related change.

MEDIA CONTACTS

BrainZell Petra Szeszula, CEO · petra@brainzell.com · +46 70 926 18 34
Stardots Daniel Petrini, CEO · daniel.petrini@stardots.se · +46 70 782 70 01